Registry of lymphoma patients in China
China Lymphoma Patient Registry Study
Peking University · NCT03313271
This study is tracking over 500 lymphoma patients in China to see how the disease progresses and how different treatments work, with the hope of improving survival rates and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT03313271 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a cohort of lymphoma patients in China to better understand disease progression, treatment, and prognosis. By following over 500 patients diagnosed with Hodgkin's or non-Hodgkin's lymphoma, the study seeks to collect comprehensive data on diagnosis, treatment, and outcomes. The goal is to bridge the gap in survival rates between China and the United States by providing essential information for clinical research and drug development. This long-term follow-up will help improve patient outcomes and quality of life.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been diagnosed with Hodgkin's or non-Hodgkin's lymphoma within the last six months.
Not a fit: Patients who do not have a confirmed diagnosis of lymphoma or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better survival rates for lymphoma patients in China.
How similar studies have performed: Other countries, like South Korea and the United States, have successfully conducted similar observational cohort studies, indicating the potential for success in this approach in China.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma * 18 years of age or older at diagnosis * The diagnosis was confirmed within 6 months before admission * Informed consent was obtained Exclusion Criteria: * There are no special exclusion criteria in this study
Where this trial is running
Beijing, Beijing Municipality
- Peking University Cancer Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Jun Zhu, Ph D — Peking University Cancer Hospital & Institute
- Study coordinator: Yuqin Song, Ph D
- Email: songyuqin622@163.com
- Phone: 0086 13683398726
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lymphoma, lymphoma, CLAP, China, patient registry